Janssen Ranks First on List of World's Most Admired Companies

Janssen Ranks First Among World's Most Admired Companies Janssen, the pharmaceutical division of Johnson & Johnson, has once again secured the top position in the pharmaceutical category of Fortune magazine's annual 'World's Most Admired Companies' survey. With this achievement, Johnson & Johnson/Janssen has maintained its place on the list for nine consecutive years. The company's commitment to innovation and forward-thinking ideas, coupled with its patient-centric and solution-focused approach, has sustained its global leadership while also contributing to its strong financial performance in 2021. Johnson & Johnson/Janssen has ranked first in the pharmaceutical category of Fortune magazine's World's Most Admired Companies list for 2022, maintaining its nine-year leadership streak in the ranking. In doing so, Johnson & Johnson has secured the 17th position in the "Top 50 All-Stars" ranking across all sectors, achieving the distinction of appearing on the list consecutively for 20 years. The Fortune World's Most Admired Companies 2022 list, announced recently, is based on survey participants' evaluation of companies in their respective sectors across nine core attributes of reputation: Human Capital Management, Asset Use, Quality of Management, Financial Soundness, Long-Term Investment Value, Global Competitiveness, Innovation, Social Responsibility, and Quality of Products/Services.

Demet Russ: "Such Success Is No Coincidence"

Demet Russ, General Manager of Janssen Turkey, stated: "At Johnson & Johnson and Janssen, we take pride in celebrating new successes thanks to our values, our science-based vision, and our patient-centric approach. This achievement is a testament to our talented workforce working with full dedication to do better; it reflects the innovation, science, and institutional culture we foster. The alignment of the evaluation criteria with our guiding principles outlined in our Credo brings us particular satisfaction. Sustaining this achievement over the years on a prestigious platform such as Fortune's World's Most Admired Companies list is no coincidence—it is proof that we are on the right path." he said.

Johnson & Johnson's Innovative Approach Contributing to Financial Performance

Johnson & Johnson, announcing its fourth quarter and full-year 2021 financial results, continues to reach patients, consumers, and healthcare providers with innovative solutions through its pharmaceutical company Janssen, Consumer Health, and Medical Devices divisions. Johnson & Johnson's fourth quarter 2021 sales reached USD 24.8 billion, with full-year sales reaching USD 93.8 billion, results the company characterizes as providing a strong performance outlook for 2022 and beyond. In its statement, the company noted that growth has been achieved by maintaining an innovative perspective globally across all segments, preserving competitive strength while providing solutions that support millions of people in living better, healthier lives, and collaborating with qualified leaders on a global scale.